RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer Dec 11, 2024 08:00AM
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial Nov 20, 2024 08:45AM
RenovoRx (RNXT) Increases Production of FDA-Cleared RenovoCath Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians Sep 25, 2024 08:32AM
RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians Sep 25, 2024 08:30AM
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York Aug 27, 2024 08:30AM
View Older Stories

Aug 14, 2024 08:30AM RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
Jul 31, 2024 08:33AM RenovoRx (RNXT) Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist
Jul 31, 2024 08:30AM RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist®
Jul 8, 2024 08:30AM RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®
Jul 8, 2024 08:30AM RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®
Jun 26, 2024 08:30AM University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial
Jun 10, 2024 08:33AM RenovoRx (RNXT) Appoints Ryan Witt as SVP of Head of Corporate Strategy and Partnerships
Jun 10, 2024 08:30AM RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
May 30, 2024 08:32AM RenovoRx (RNXT) CEO Issues Update Letter
May 30, 2024 08:30AM RenovoRx CEO Issues Update Letter to Shareholders
May 21, 2024 09:00AM Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery
May 14, 2024 09:00AM RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024
May 2, 2024 09:00AM RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024
Apr 18, 2024 08:31AM RenovoRx (RNXT) Regains Compliance with Nasdaq Stockholders’ Equity Requirement
Apr 18, 2024 08:30AM RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
Apr 16, 2024 08:30AM RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
Apr 15, 2024 08:00AM RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
Apr 8, 2024 08:31AM RenovoRx (RNXT) Announces $11.1 Million at Market Private Placement
Apr 8, 2024 08:30AM RenovoRx Announces $11.1 Million at Market Private Placement
Apr 5, 2024 08:30AM RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
Mar 12, 2024 09:00AM RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
Mar 8, 2024 04:05PM RenovoRx (RNXT) Announces Leadership Changes
Mar 8, 2024 04:05PM RenovoRx Highlights Key Leadership Promotions
Feb 6, 2024 08:30AM RenovoRx CEO Issues Letter to Shareholders
Jan 29, 2024 08:30AM RenovoRx Closes $6.1 Million Private Placement
Dec 21, 2023 08:30AM RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
Dec 19, 2023 08:30AM RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
Dec 13, 2023 08:31AM RenovoRx (RNXT) Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
Dec 13, 2023 08:31AM RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
Nov 16, 2023 08:35AM RenovoRx (RNXT) Appoints Michel Ducreux to its Board
Nov 16, 2023 08:35AM RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
Nov 14, 2023 08:30AM RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights
Oct 2, 2023 08:30AM RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023
Aug 17, 2023 08:30AM RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights
Jul 31, 2023 08:30AM RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference
Jul 20, 2023 08:03AM RenovoRx (RNXT) and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using TAMP Platform
Jul 20, 2023 08:00AM RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
Jun 29, 2023 08:03AM RenovoRx (RNXT) Announces New Positive Interim Phase III Data Demonstrating RenovoGem Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer
Jun 29, 2023 08:00AM RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer
Jun 20, 2023 08:30AM RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board
Jun 12, 2023 08:30AM RenovoRx Announces ROTH Capital Key Opinion Leader (KOL) Webcast on June 15
Jun 1, 2023 08:30AM RenovoRx Initiates Patient Enrollment at University of Texas Southwestern Medical Center for Pivotal Phase III TIGeR-PaC Clinical Trial
May 25, 2023 08:30AM RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer
May 24, 2023 08:30AM RenovoRx to Present at the LD Micro Invitational XIII Conference
May 15, 2023 08:30AM RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights
May 1, 2023 08:30AM RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride® Event
Apr 28, 2023 08:30AM RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023
Apr 27, 2023 08:30AM RenovoRx (RNXT) Appoints Robert J. Spiegel to its Board
Apr 27, 2023 08:30AM RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors
Apr 14, 2023 08:30AM RenovoRx (RNXT) Presenting Phase III Clinical Trial Interim Analysis Data
View Older Stories